SEARCH

SEARCH BY CITATION

References

  • Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM. (1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA 96:1526815273.
  • French JA, Costantini C, Brodsky A, von Rosenstiel P. (2010) Adjunctive brivaracetam for refractory partial-onset seizures. A randomized, controlled trial. Neurology 75:519525.
  • Gillard M, Fuks B, Leclercq K, Matagne A. (2011) Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol 664:3644.
  • Guekht AB, Korczyn AD, Bondareva IB, Gusev EI. (2010) Placebo responses in randomized trials of antiepileptic drugs. Epilepsy Behav 17:6469.
  • International League Against Epilepsy. (1981) Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 22:489501.
  • International League Against Epilepsy. (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30:389399.
  • Johnson ME, Lu S, Merschhemke M. (2010) The impact of standardization on the magnitude of treatment effect when analyzing log-transformed seizure outcome. American Epilepsy Society Annual Meeting.
  • Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, Talaga P, Klitgaard H. (2008) SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54:715720.
  • Kwan P, Johnson ME, Falter U, Pieteur VB, Brodsky A, von Rosensteil P. (2009) Safety and tolerability of brivaracetam as adjunctive treatment in adults with refractory epilepsy: randomized, doubleblind, placebo-controlled trial. Epilepsia 50(Suppl. 11):107108.
  • Matagne A, Margineanu D-G, Kenda B, Michel P, Klitgaard H. (2008) Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 154:16621671.
  • Rheims S, Perucca E, Cucherat M, Ryvlin P. (2011) Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 52:219233.
  • Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. (2008) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males. Br J Clin Pharmacol 66:7175.
  • Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E, Riethuisen JM, Stockis A. (2007) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol 63:680688.
  • Sargentini-Maier ML, Espie P, Coquette A, Stockis A. (2008) Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 36:3645.
  • van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. (2013) Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 54:8997.
  • van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA. (2009) Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia 50:422433.
  • Werhahn KJ, Biton V, Johnson ME, Merschhemke M, Lu S; N01252 and N01253 Brivaracetam Study Group (2010) Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from two randomized, double-blind, placebo-controlled trials. Epilepsia 51(Suppl. 4):150.